Karus Therapeutics

Shanghai-based Convalife Pharmaceuticals has entered into a licensing agreement with UK-based Karus Therapeutics Ltd, acquiring global patents, development, and commercialization rights to CVL237 (KA2237). Financial terms were not disclosed. Drug ProfileCVL237 is a dual selective inhibitor of phosphatidylinositol-3-kinase (PI3K) β/δ. It is advancing into Phase II trials in China and…